Lynette Stanton

Lynette Stanton was the in-house counsel for Douglas Pharmaceuticals during the discussions surrounding the Trans-Pacific Partnership (TPP), which posed potential challenges for the company due to its focus on generic drug production and the implications of extended patent protections favored by larger pharmaceutical firms.